Search
Dexamethasone Treatment Options
A collection of 1455 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
1021 - 1032 of 1455
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
Completed
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: Sarcoma Oncology Center, Santa Monica, California +73 locations
Conditions: Chemotherapy-Induced Nausea and Vomiting
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
Completed
This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain and dry mouth caused by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2018
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Chalazion Conservative Treatment Trial
Completed
An eyelid stye, or chalazion, is the most common eyelid ailment, and is caused by the blockage of one of the oil secreting glands of the eyelid (meibomian glands). This leads to a typically painful, swollen, and red eyelid bump that lasts from days to weeks and months. The chalazion may cause tearing, pressure on the cornea, and irritation, all of which contribute to its morbidity. There are many anecdotal first line treatments for this condition, including warm compresses to the eyelid, topical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2018
Locations: Elmhurst Hospital Center, Elmhurst, New York +2 locations
Conditions: Chalazion Unspecified Eye, Unspecified Eyelid, Chalazion Left Eye, Unspecified Eyelid, Chalazion Right Eye, Unspecified Eyelid, Chalazion Both Eyes
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
Completed
The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed. The safety of the drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Terminated
This clinical trial is for subjects with multiple myeloma that has returned after treatment (relapsed) or did not respond to prior treatment (refractory). The study is in two parts, Phase I and Phase II. Phase I will determine the maximum tolerated dose of romidepsin in combination with pomalidomide and dexamethasone. The purpose of Phase II is to evaluate the effectiveness of combining romidepsin with pomalidomide and dexamethasone. The hypothesis is that overall response in a cohort of patient... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/31/2018
Locations: Weill Cornell Medical College, New York, New York
Conditions: Multiple Myeloma
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
Terminated
Study Objectives
1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide (Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or refractory multiple myeloma (MM) who have failed prior treatment with both lenalidomide and thalidomide when used as monotherapies.
2. To evaluate the safety of the combination of lenalidomide, dexamethasone, and thalidomide as a therapy for patients with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2018
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Multiple Myeloma
Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery
Withdrawn
The novel introduction of various chest wall blocks such as the Pecs I and II/modified Pecs blocks as well as the Serratus Anterior Plane Block have extended the application of perioperative regional anesthesia to provide analgesia for breast surgery. However, to our knowledge, there are no large studies that truly delineate the optimal injection site for the Serratus Anterior Plane Block.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/29/2018
Locations: UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama
Conditions: Pain, Postoperative
Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
Completed
Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/17/2018
Locations: Site 901, Jacksonville, Florida
Conditions: Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Completed
This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from div... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +5 locations
Conditions: Recurrent Plasma Cell Myeloma
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Terminated
The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age. The safety of these drug combinations will also be studied.
Augmented BFM is made up of daunorubicin, vincristine, prednisone, dexamethasone, PEG asparaginase, and methotrexate.
Gender:
ALL
Ages:
Between 12 years and 30 years
Trial Updated:
05/09/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
Completed
RATIONALE: Some cancers need growth factors which are made by the body's white blood cells to keep growing.Anakinra may interfere with the growth factor and stop multiple myeloma from growing. Dexamethasone may stop cancer cells from growing. Giving anakinra together with dexamethasone may be an effective treatment for multiple myeloma.
PURPOSE: This phase II trial is studying how well anakinra works when given with or without dexamethasone in treating patients with smoldering myeloma or indole... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/08/2018
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
Terminated
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma. Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as obinutuzumab, may find cancer cells and help kill them. Giving ben... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
05/07/2018
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Diffuse Large B-Cell Lymphoma
1021 - 1032 of 1455